20 Papers
92 Citations
Lan Shao is an academic researcher from Zhejiang Chinese Medical University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 7, co-authored 12 publications.
Chat about Author
Papers
Cutaneous metastasis as a initial presentation in advanced non-small cell lung cancer and its poor survival prognosis.
TL;DR: This retrospective study indicated that 2.8 % of advanced NSCLC patients showed cutaneous metastases as an initial presentation, and multivariate analyses revealed that performance status and chemotherapy efficacy statistically associated with overall survival.
51
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma
TL;DR: The frequency of EGFR mutation and clinical characteristics of the EGFR mutants in ASC are similar to those of Asian patients with adenocarcinoma, suggesting that TKI is an effective treatment for ASC.
33
Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma
TL;DR: Preoperative, high serum CRP is an independent determinant of poor prognosis in early‐stage ESCC, and is found to be an independent prognostic factor for poor survival.
18
•Journal Article
Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Lan Shao,Beibei Zhang,Chunxiao He,Baochai Lin,Zhengbo Song,Guangyuan Lou,Xinmin Yu,Yiping Zhang +7 more
TL;DR: In this article, the authors performed a retrospective study of the efficacy and safety of icotinib monotherapy in a different and more recent sample of Chinese patients, and found that the drug is an effective and well tolerated regimen for Chinese patients with NSCLC after the failure of chemotherapy.
15
•Journal Article
Efficacy and safety of icotinib in 299 patients with advanced non-small cell lung cancer after failure of chemotherapy
TL;DR: Icotinib monotherapy is an effective and well tolerated regimen for Chinese patients with NSCLC after the failure of chemotherapy and it is a promising agent and further study in properly conducted trials with larger patient samples and other ethnic groups is warranted.
14